Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships

This article was originally published in The Pink Sheet Daily

Executive Summary

On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

You may also be interested in...



Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value

Pfizer CEO Ian Read provided Wall Street with more clarity on his vision for the company as it moves beyond Lipitor into a new era. Pfizer will have two primary businesses, he said, an innovative pharmaceutical engine and a value business.

Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.

Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference

WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073864

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel